ID   G3P_RAT                 Reviewed;         333 AA.
AC   P04797; P09328; Q5M916; Q9QWU4;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   29-MAY-2024, entry version 216.
DE   RecName: Full=Glyceraldehyde-3-phosphate dehydrogenase;
DE            Short=GAPDH;
DE            EC=1.2.1.12 {ECO:0000305|PubMed:17934141};
DE   AltName: Full=38 kDa BFA-dependent ADP-ribosylation substrate;
DE   AltName: Full=BARS-38;
DE   AltName: Full=Peptidyl-cysteine S-nitrosylase GAPDH {ECO:0000305};
DE            EC=2.6.99.- {ECO:0000269|PubMed:20972425};
GN   Name=Gapdh; Synonyms=Gapd;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Muscle;
RX   PubMed=2987824; DOI=10.1093/nar/13.5.1431;
RA   Fort P., Marty L., Piechaczyk M., el Sabrouty S., Dani C., Jeanteur P.,
RA   Blanchard J.-M.;
RT   "Various rat adult tissues express only one major mRNA species from the
RT   glyceraldehyde-3-phosphate-dehydrogenase multigenic family.";
RL   Nucleic Acids Res. 13:1431-1442(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=2987855; DOI=10.1093/nar/13.7.2485;
RA   Tso J.Y., Sun X.-H., Kao T.-H., Reece K.S., Wu R.;
RT   "Isolation and characterization of rat and human glyceraldehyde-3-phosphate
RT   dehydrogenase cDNAs: genomic complexity and molecular evolution of the
RT   gene.";
RL   Nucleic Acids Res. 13:2485-2502(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   STRAIN=Sprague-Dawley; TISSUE=Cerebellum;
RX   PubMed=10424669; DOI=10.1097/00001756-199907130-00007;
RA   Tajima H., Tsuchiya K., Yamada M., Kondo K., Katsube N., Ishitani R.;
RT   "Over-expression of GAPDH induces apoptosis in COS-7 cells transfected with
RT   cloned GAPDH cDNAs.";
RL   NeuroReport 10:2029-2033(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Zheng J., Ramirez V.D.;
RT   "Isolation of a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
RT   isoform from rat brain by a rapid PCR-based cloning method and its
RT   expression by RT-PCR.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Pituitary anterior lobe;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 65-105; 116-137; 144-184; 233-246 AND 308-321, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Hippocampus, and Spinal cord;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 235-333.
RC   TISSUE=Brain;
RX   PubMed=3585333; DOI=10.1111/j.1471-4159.1987.tb03420.x;
RA   Leung T.K.C., Hall C., Monfries C., Lim L.;
RT   "Trifluoperazine activates and releases latent ATP-generating enzymes
RT   associated with the synaptic plasma membrane.";
RL   J. Neurochem. 49:232-238(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 261-323, AND TISSUE SPECIFICITY.
RC   TISSUE=Glial tumor;
RX   PubMed=6548307; DOI=10.1093/nar/12.18.6951;
RA   Piechaczyk M., Blanchard J.-M., Marty L., Dani C., Panabieres F.,
RA   el Sabrouty S., Fort P., Jeanteur P.;
RT   "Post-transcriptional regulation of glyceraldehyde-3-phosphate-
RT   dehydrogenase gene expression in rat tissues.";
RL   Nucleic Acids Res. 12:6951-6963(1984).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 267-333.
RX   PubMed=2413848; DOI=10.1016/0006-291x(85)91310-5;
RA   Maehara Y., Fujiyoshi T., Takahashi K., Yamamoto M., Endo H.;
RT   "1.5 kb mRNA abundantly expressed in rat tumors encodes a 37 kilodalton
RT   protein in vitro.";
RL   Biochem. Biophys. Res. Commun. 131:800-805(1985).
RN   [10]
RP   S-NITROSYLATION.
RX   PubMed=1281150; DOI=10.1016/s0021-9258(19)73985-4;
RA   Molina y Vedia L., McDonald B., Reep B., Brune B., Di Silvio M.,
RA   Billiar T.R., Lapetina E.G.;
RT   "Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate
RT   dehydrogenase inhibits enzymatic activity and increases endogenous ADP-
RT   ribosylation.";
RL   J. Biol. Chem. 267:24929-24932(1992).
RN   [11]
RP   S-NITROSYLATION AT CYS-150, ADP-RIBOSYLATION AT CYS-150, LACK OF
RP   S-NITROSYLATION AT CYS-154, AND ACTIVE SITE.
RX   PubMed=8626764; DOI=10.1074/jbc.271.8.4209;
RA   Mohr S., Stamler J.S., Brune B.;
RT   "Posttranslational modification of glyceraldehyde-3-phosphate dehydrogenase
RT   by S-nitrosylation and subsequent NADH attachment.";
RL   J. Biol. Chem. 271:4209-4214(1996).
RN   [12]
RP   FUNCTION, INTERACTION WITH CHP1, ASSOCIATION WITH MICROTUBULES, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15312048; DOI=10.1042/bj20040622;
RA   Andrade J., Pearce S.T., Zhao H., Barroso M.;
RT   "Interactions among p22, glyceraldehyde-3-phosphate dehydrogenase and
RT   microtubules.";
RL   Biochem. J. 384:327-336(2004).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH SIAH1, S-NITROSYLATION AT
RP   CYS-150, AND MUTAGENESIS OF CYS-150; LYS-225; PRO-234 AND THR-235.
RX   PubMed=15951807; DOI=10.1038/ncb1268;
RA   Hara M.R., Agrawal N., Kim S.F., Cascio M.B., Fujimuro M., Ozeki Y.,
RA   Takahashi M., Cheah J.H., Tankou S.K., Hester L.D., Ferris C.D.,
RA   Hayward S.D., Snyder S.H., Sawa A.;
RT   "S-nitrosylated GAPDH initiates apoptotic cell death by nuclear
RT   translocation following Siah1 binding.";
RL   Nat. Cell Biol. 7:665-674(2005).
RN   [14]
RP   SUCCINATION AT CYS-150 AND CYS-245, FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=17934141; DOI=10.2337/db07-0838;
RA   Blatnik M., Frizzell N., Thorpe S.R., Baynes J.W.;
RT   "Inactivation of glyceraldehyde-3-phosphate dehydrogenase by fumarate in
RT   diabetes: formation of S-(2-succinyl)cysteine, a novel chemical
RT   modification of protein and possible biomarker of mitochondrial stress.";
RL   Diabetes 57:41-49(2008).
RN   [15]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH RILPL1 AND SIAH1.
RX   PubMed=19607794; DOI=10.1016/j.neuron.2009.05.024;
RA   Sen N., Hara M.R., Ahmad A.S., Cascio M.B., Kamiya A., Ehmsen J.T.,
RA   Agrawal N., Hester L., Dore S., Snyder S.H., Sawa A.;
RT   "GOSPEL: a neuroprotective protein that binds to GAPDH upon S-
RT   nitrosylation.";
RL   Neuron 63:81-91(2009).
RN   [16]
RP   FUNCTION AS NITROSYLASE, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION,
RP   S-NITROSYLATION AT CYS-150, AND MUTAGENESIS OF SER-149; CYS-150; THR-151
RP   AND THR-152.
RX   PubMed=20972425; DOI=10.1038/ncb2114;
RA   Kornberg M.D., Sen N., Hara M.R., Juluri K.R., Nguyen J.V., Snowman A.M.,
RA   Law L., Hester L.D., Snyder S.H.;
RT   "GAPDH mediates nitrosylation of nuclear proteins.";
RL   Nat. Cell Biol. 12:1094-1100(2010).
CC   -!- FUNCTION: Has both glyceraldehyde-3-phosphate dehydrogenase and
CC       nitrosylase activities, thereby playing a role in glycolysis and
CC       nuclear functions, respectively (PubMed:15951807, PubMed:17934141,
CC       PubMed:20972425). Glyceraldehyde-3-phosphate dehydrogenase is a key
CC       enzyme in glycolysis that catalyzes the first step of the pathway by
CC       converting D-glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-
CC       glyceroyl phosphate (PubMed:17934141). Modulates the organization and
CC       assembly of the cytoskeleton. Facilitates the CHP1-dependent
CC       microtubule and membrane associations through its ability to stimulate
CC       the binding of CHP1 to microtubules (PubMed:15312048). Component of the
CC       GAIT (gamma interferon-activated inhibitor of translation) complex
CC       which mediates interferon-gamma-induced transcript-selective
CC       translation inhibition in inflammation processes. Upon interferon-gamma
CC       treatment assembles into the GAIT complex which binds to stem loop-
CC       containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs
CC       (such as ceruplasmin) and suppresses their translation (By similarity).
CC       Also plays a role in innate immunity by promoting TNF-induced NF-kappa-
CC       B activation and type I interferon production, via interaction with
CC       TRAF2 and TRAF3, respectively (By similarity). Participates in nuclear
CC       events including transcription, RNA transport, DNA replication and
CC       apoptosis (PubMed:10424669, PubMed:15951807, PubMed:20972425). Nuclear
CC       functions are probably due to the nitrosylase activity that mediates
CC       cysteine S-nitrosylation of nuclear target proteins such as SIRT1,
CC       HDAC2 and PRKDC (PubMed:15951807, PubMed:20972425).
CC       {ECO:0000250|UniProtKB:P04406, ECO:0000250|UniProtKB:P10096,
CC       ECO:0000269|PubMed:10424669, ECO:0000269|PubMed:15312048,
CC       ECO:0000269|PubMed:15951807, ECO:0000269|PubMed:17934141,
CC       ECO:0000269|PubMed:20972425}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-glyceraldehyde 3-phosphate + NAD(+) + phosphate = (2R)-3-
CC         phospho-glyceroyl phosphate + H(+) + NADH; Xref=Rhea:RHEA:10300,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:43474, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57604, ChEBI:CHEBI:57945, ChEBI:CHEBI:59776; EC=1.2.1.12;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10009,
CC         ECO:0000305|PubMed:17934141};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-cysteinyl-[protein] + S-nitroso-L-cysteinyl-[GAPDH] = L-
CC         cysteinyl-[GAPDH] + S-nitroso-L-cysteinyl-[protein];
CC         Xref=Rhea:RHEA:66684, Rhea:RHEA-COMP:10131, Rhea:RHEA-COMP:17089,
CC         Rhea:RHEA-COMP:17090, Rhea:RHEA-COMP:17091, ChEBI:CHEBI:29950,
CC         ChEBI:CHEBI:149494; Evidence={ECO:0000269|PubMed:20972425};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66685;
CC         Evidence={ECO:0000269|PubMed:20972425};
CC   -!- ACTIVITY REGULATION: Glyceraldehyde-3-phosphate dehydrogenase activity
CC       is inhibited by fumarate, via the formation of S-(2-succinyl)cysteine
CC       residues. {ECO:0000269|PubMed:17934141}.
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
CC       glyceraldehyde 3-phosphate: step 1/5.
CC   -!- SUBUNIT: Homotetramer (By similarity). Interacts with TPPP; the
CC       interaction is direct (By similarity). Interacts (when S-nitrosylated)
CC       with SIAH1; leading to nuclear translocation (PubMed:15951807,
CC       PubMed:19607794). Interacts with RILPL1/GOSPEL, leading to prevent the
CC       interaction between GAPDH and SIAH1 and prevent nuclear translocation
CC       (PubMed:19607794). Interacts with CHP1; the interaction increases the
CC       binding of CHP1 with microtubules (PubMed:15312048). Associates with
CC       microtubules (PubMed:15312048). Interacts with EIF1AD, USP25, PRKCI and
CC       WARS1. Interacts with phosphorylated RPL13A; inhibited by oxidatively-
CC       modified low-densitity lipoprotein (LDL(ox)). Component of the GAIT
CC       complex. Interacts with FKBP6; leading to inhibit GAPDH catalytic
CC       activity. Interacts with TRAF2, promoting TRAF2 ubiquitination.
CC       Interacts with TRAF3, promoting TRAF3 ubiquitination (By similarity).
CC       {ECO:0000250|UniProtKB:P04406, ECO:0000250|UniProtKB:P10096,
CC       ECO:0000269|PubMed:15312048, ECO:0000269|PubMed:15951807,
CC       ECO:0000269|PubMed:19607794}.
CC   -!- INTERACTION:
CC       P04797; P47196: Akt1; NbExp=3; IntAct=EBI-349219, EBI-7204362;
CC       P04797; P61023: Chp1; NbExp=3; IntAct=EBI-349219, EBI-917838;
CC       P04797; Q80Z30: Ppm1e; NbExp=5; IntAct=EBI-349219, EBI-7473061;
CC       P04797; P19357: Slc2a4; NbExp=2; IntAct=EBI-349219, EBI-915426;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:15312048,
CC       ECO:0000269|PubMed:15951807, ECO:0000269|PubMed:19607794}. Cytoplasm,
CC       cytoskeleton {ECO:0000269|PubMed:15312048}. Nucleus
CC       {ECO:0000269|PubMed:15951807, ECO:0000269|PubMed:19607794,
CC       ECO:0000269|PubMed:20972425}. Note=Translocates to the nucleus
CC       following S-nitrosylation and interaction with SIAH1, which contains a
CC       nuclear localization signal (PubMed:15951807). Colocalizes with CHP1 to
CC       small punctate structures along the microtubules tracks
CC       (PubMed:15312048). {ECO:0000269|PubMed:15312048,
CC       ECO:0000269|PubMed:15951807}.
CC   -!- TISSUE SPECIFICITY: High levels in skeletal muscle and heart, low
CC       levels in liver, brain, and kidney. {ECO:0000269|PubMed:6548307}.
CC   -!- DOMAIN: The [IL]-x-C-x-x-[DE] motif is a proposed target motif for
CC       cysteine S-nitrosylation mediated by the iNOS-S100A8/A9
CC       transnitrosylase complex. {ECO:0000250|UniProtKB:P04406}.
CC   -!- PTM: S-nitrosylation of Cys-150 leads to interaction with SIAH1,
CC       followed by translocation to the nucleus (PubMed:1281150,
CC       PubMed:15951807, PubMed:20972425, PubMed:8626764). The effect of S-
CC       nitrosylation on enzymatic activity is unclear: according to some
CC       authors, it inhibits enzymatic activity and increases endogenous ADP-
CC       ribosylation, inhibiting the enzyme in a non-reversible manner
CC       (PubMed:8626764). According to others, it does not affect glycolysis
CC       (PubMed:15951807). ADP-ribosylation is likely to be a
CC       pathophysiological event associated with inhibition of gluconeogenesis
CC       (PubMed:8626764). S-nitrosylation of Cys-245 is induced by interferon-
CC       gamma and LDL(ox) implicating the iNOS-S100A8/9 transnitrosylase
CC       complex and seems to prevent interaction with phosphorylated RPL13A and
CC       to interfere with GAIT complex activity (By similarity).
CC       {ECO:0000250|UniProtKB:P04406, ECO:0000269|PubMed:1281150,
CC       ECO:0000269|PubMed:15951807, ECO:0000269|PubMed:20972425,
CC       ECO:0000269|PubMed:8626764}.
CC   -!- PTM: ISGylated. {ECO:0000250|UniProtKB:P04406}.
CC   -!- PTM: Sulfhydration at Cys-150 increases catalytic activity.
CC       {ECO:0000250|UniProtKB:P16858}.
CC   -!- PTM: Oxidative stress can promote the formation of high molecular
CC       weight disulfide-linked GAPDH aggregates, through a process called
CC       nucleocytoplasmic coagulation. {ECO:0000250|UniProtKB:P04406}.
CC   -!- PTM: Succination of Cys-150 and Cys-245 by the Krebs cycle intermediate
CC       fumarate, which leads to S-(2-succinyl)cysteine residues, inhibits
CC       glyceraldehyde-3-phosphate dehydrogenase activity. Fumarate
CC       concentration as well as succination of cysteine residues in GAPDH is
CC       significantly increased in muscle of diabetic rats. It was proposed
CC       that the S-(2-succinyl)cysteine chemical modification may be a useful
CC       biomarker of mitochondrial and oxidative stress in diabetes and that
CC       succination of GAPDH and other thiol proteins by fumarate may
CC       contribute to the metabolic changes underlying the development of
CC       diabetes complications. {ECO:0000269|PubMed:17934141}.
CC   -!- SIMILARITY: Belongs to the glyceraldehyde-3-phosphate dehydrogenase
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X02231; CAA26150.1; -; mRNA.
DR   EMBL; M17701; AAA41193.1; -; mRNA.
DR   EMBL; AB017801; BAB11748.1; -; mRNA.
DR   EMBL; AF106860; AAD08929.2; -; mRNA.
DR   EMBL; BC059110; AAH59110.1; -; mRNA.
DR   EMBL; BC087743; AAH87743.1; -; mRNA.
DR   EMBL; M29341; AAA40814.1; -; mRNA.
DR   EMBL; M11561; AAA41795.1; -; mRNA.
DR   PIR; A23013; DERTG.
DR   RefSeq; NP_058704.1; NM_017008.4.
DR   RefSeq; XP_017447924.1; XM_017592435.1.
DR   RefSeq; XP_017458425.1; XM_017602936.1.
DR   AlphaFoldDB; P04797; -.
DR   SMR; P04797; -.
DR   BioGRID; 246554; 14.
DR   CORUM; P04797; -.
DR   IntAct; P04797; 10.
DR   MINT; P04797; -.
DR   STRING; 10116.ENSRNOP00000040878; -.
DR   ChEMBL; CHEMBL2176832; -.
DR   MoonProt; P04797; -.
DR   GlyGen; P04797; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P04797; -.
DR   PhosphoSitePlus; P04797; -.
DR   jPOST; P04797; -.
DR   PaxDb; 10116-ENSRNOP00000040878; -.
DR   Ensembl; ENSRNOT00055010101; ENSRNOP00055007825; ENSRNOG00055006222.
DR   Ensembl; ENSRNOT00055015786; ENSRNOP00055012671; ENSRNOG00055009333.
DR   Ensembl; ENSRNOT00055053257; ENSRNOP00055044021; ENSRNOG00055030697.
DR   Ensembl; ENSRNOT00060056622; ENSRNOP00060046787; ENSRNOG00060032665.
DR   Ensembl; ENSRNOT00065034039; ENSRNOP00065027256; ENSRNOG00065020177.
DR   Ensembl; ENSRNOT00065056696; ENSRNOP00065046675; ENSRNOG00065032955.
DR   GeneID; 24383; -.
DR   KEGG; rno:24383; -.
DR   UCSC; RGD:2661; rat.
DR   AGR; RGD:2661; -.
DR   CTD; 2597; -.
DR   RGD; 2661; Gapdh.
DR   VEuPathDB; HostDB:ENSRNOG00000018630; -.
DR   eggNOG; KOG0657; Eukaryota.
DR   HOGENOM; CLU_030140_0_1_1; -.
DR   InParanoid; P04797; -.
DR   OrthoDB; 275384at2759; -.
DR   PhylomeDB; P04797; -.
DR   TreeFam; TF300533; -.
DR   BRENDA; 1.2.1.12; 5301.
DR   Reactome; R-RNO-70171; Glycolysis.
DR   Reactome; R-RNO-70263; Gluconeogenesis.
DR   SABIO-RK; P04797; -.
DR   UniPathway; UPA00109; UER00184.
DR   PRO; PR:P04797; -.
DR   Proteomes; UP000002494; Chromosome 4.
DR   Bgee; ENSRNOG00000018630; Expressed in skeletal muscle tissue and 18 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0097452; C:GAIT complex; ISS:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0005811; C:lipid droplet; ISO:RGD.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0099092; C:postsynaptic density, intracellular component; IDA:SynGO.
DR   GO; GO:1990904; C:ribonucleoprotein complex; ISO:RGD.
DR   GO; GO:0019828; F:aspartic-type endopeptidase inhibitor activity; ISO:RGD.
DR   GO; GO:0097718; F:disordered domain specific binding; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0004365; F:glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:RGD.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0051287; F:NAD binding; IEA:InterPro.
DR   GO; GO:0050661; F:NADP binding; IEA:InterPro.
DR   GO; GO:0035605; F:peptidyl-cysteine S-nitrosylase activity; IDA:UniProtKB.
DR   GO; GO:0061844; P:antimicrobial humoral immune response mediated by antimicrobial peptide; ISO:RGD.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IMP:RGD.
DR   GO; GO:0061621; P:canonical glycolysis; ISO:RGD.
DR   GO; GO:0071346; P:cellular response to type II interferon; ISO:RGD.
DR   GO; GO:0007565; P:female pregnancy; IEP:RGD.
DR   GO; GO:0006094; P:gluconeogenesis; IDA:RGD.
DR   GO; GO:0006096; P:glycolytic process; IMP:RGD.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; ISO:RGD.
DR   GO; GO:1905460; P:negative regulation of vascular associated smooth muscle cell apoptotic process; IMP:RGD.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; IDA:UniProtKB.
DR   GO; GO:0035606; P:peptidyl-cysteine S-trans-nitrosylation; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISS:UniProtKB.
DR   GO; GO:0001819; P:positive regulation of cytokine production; ISO:RGD.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; ISS:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1.
DR   InterPro; IPR020831; GlycerAld/Erythrose_P_DH.
DR   InterPro; IPR020830; GlycerAld_3-P_DH_AS.
DR   InterPro; IPR020829; GlycerAld_3-P_DH_cat.
DR   InterPro; IPR020828; GlycerAld_3-P_DH_NAD(P)-bd.
DR   InterPro; IPR006424; Glyceraldehyde-3-P_DH_1.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   NCBIfam; TIGR01534; GAPDH-I; 1.
DR   PANTHER; PTHR10836; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE; 1.
DR   PANTHER; PTHR10836:SF111; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; 1.
DR   Pfam; PF02800; Gp_dh_C; 1.
DR   Pfam; PF00044; Gp_dh_N; 1.
DR   PIRSF; PIRSF000149; GAP_DH; 1.
DR   PRINTS; PR00078; G3PDHDRGNASE.
DR   SMART; SM00846; Gp_dh_N; 1.
DR   SUPFAM; SSF55347; Glyceraldehyde-3-phosphate dehydrogenase-like, C-terminal domain; 1.
DR   SUPFAM; SSF51735; NAD(P)-binding Rossmann-fold domains; 1.
DR   PROSITE; PS00071; GAPDH; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ADP-ribosylation; Apoptosis; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Glycolysis; Immunity; Innate immunity;
KW   Isopeptide bond; Methylation; NAD; Nucleus; Oxidoreductase; Phosphoprotein;
KW   Reference proteome; S-nitrosylation; Transferase; Translation regulation;
KW   Ubl conjugation.
FT   CHAIN           1..333
FT                   /note="Glyceraldehyde-3-phosphate dehydrogenase"
FT                   /id="PRO_0000145494"
FT   REGION          1..146
FT                   /note="Interaction with WARS1"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOTIF           243..248
FT                   /note="[IL]-x-C-x-x-[DE] motif"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   ACT_SITE        150
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10009,
FT                   ECO:0000269|PubMed:8626764"
FT   BINDING         11..12
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   BINDING         33
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   BINDING         78
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   BINDING         120
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   BINDING         149..151
FT                   /ligand="D-glyceraldehyde 3-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:59776"
FT                   /evidence="ECO:0000250|UniProtKB:P22513"
FT   BINDING         180
FT                   /ligand="D-glyceraldehyde 3-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:59776"
FT                   /evidence="ECO:0000250|UniProtKB:P22513"
FT   BINDING         209..210
FT                   /ligand="D-glyceraldehyde 3-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:59776"
FT                   /evidence="ECO:0000250|UniProtKB:P22513"
FT   BINDING         232
FT                   /ligand="D-glyceraldehyde 3-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:59776"
FT                   /evidence="ECO:0000250|UniProtKB:P22513"
FT   BINDING         314
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   SITE            154
FT                   /note="Not nitrosylated"
FT                   /evidence="ECO:0000269|PubMed:8626764"
FT   SITE            177
FT                   /note="Activates thiol group during catalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         3
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         7
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         40
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         59
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         62
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         64
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         68
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         73
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         120
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         146
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         147
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         149
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         150
FT                   /note="ADP-ribosylcysteine; by autocatalysis; in
FT                   irreversibly inhibited form"
FT                   /evidence="ECO:0000269|PubMed:8626764"
FT   MOD_RES         150
FT                   /note="Cysteine persulfide"
FT                   /evidence="ECO:0000250|UniProtKB:P16858"
FT   MOD_RES         150
FT                   /note="S-(2-succinyl)cysteine"
FT                   /evidence="ECO:0000269|PubMed:17934141"
FT   MOD_RES         150
FT                   /note="S-nitrosocysteine; in reversibly inhibited form"
FT                   /evidence="ECO:0000269|PubMed:15951807,
FT                   ECO:0000269|PubMed:20972425, ECO:0000269|PubMed:8626764"
FT   MOD_RES         151
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         153
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         175
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         180
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         182
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         192
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         192
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         192
FT                   /note="N6-malonyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         209
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         213
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         213
FT                   /note="N6-malonyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         217
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         223
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         225
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         225
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         227
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         235
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         239
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         245
FT                   /note="S-(2-succinyl)cysteine"
FT                   /evidence="ECO:0000269|PubMed:17934141"
FT   MOD_RES         245
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         252
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         258
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         261
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         310
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         314
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MOD_RES         332
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   CROSSLNK        184
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P04406"
FT   MUTAGEN         149
FT                   /note="S->A: Does not affect interaction with SIRT1."
FT                   /evidence="ECO:0000269|PubMed:20972425"
FT   MUTAGEN         150
FT                   /note="C->S: Abolishes S-nitrosylation and subsequent
FT                   nuclear translocation."
FT                   /evidence="ECO:0000269|PubMed:15951807,
FT                   ECO:0000269|PubMed:20972425"
FT   MUTAGEN         151
FT                   /note="T->A: Does not affect interaction with SIRT1."
FT                   /evidence="ECO:0000269|PubMed:20972425"
FT   MUTAGEN         152
FT                   /note="T->A: Abolishes interaction and subsequent
FT                   nitrosylation of SIRT1."
FT                   /evidence="ECO:0000269|PubMed:20972425"
FT   MUTAGEN         225
FT                   /note="K->A: Abolishes interaction with SIAH1."
FT                   /evidence="ECO:0000269|PubMed:15951807"
FT   MUTAGEN         234
FT                   /note="P->A: Does not affect interaction with SIAH1."
FT                   /evidence="ECO:0000269|PubMed:15951807"
FT   MUTAGEN         235
FT                   /note="T->A: Does not affect interaction with SIAH1."
FT                   /evidence="ECO:0000269|PubMed:15951807"
FT   CONFLICT        81..82
FT                   /note="AN -> VK (in Ref. 1; AAA41193)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        129
FT                   /note="F -> L (in Ref. 5; AAH87743)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        305
FT                   /note="F -> I (in Ref. 1; AAA41193 and 8; CAA26150)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   333 AA;  35828 MW;  D9E5ED4F38544C77 CRC64;
     MVKVGVNGFG RIGRLVTRAA FSCDKVDIVA INDPFIDLNY MVYMFQYDST HGKFNGTVKA
     ENGKLVINGK PITIFQERDP ANIKWGDAGA EYVVESTGVF TTMEKAGAHL KGGAKRVIIS
     APSADAPMFV MGVNHEKYDN SLKIVSNASC TTNCLAPLAK VIHDNFGIVE GLMTTVHAIT
     ATQKTVDGPS GKLWRDGRGA AQNIIPASTG AAKAVGKVIP ELNGKLTGMA FRVPTPNVSV
     VDLTCRLEKP AKYDDIKKVV KQAAEGPLKG ILGYTEDQVV SCDFNSNSHS STFDAGAGIA
     LNDNFVKLIS WYDNEYGYSN RVVDLMAYMA SKE
//
